MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318784 | Name: Suramin Hexasodium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Suramin is an antiparasitic drug. The mechanism of action for suramin is unclear, however, it is thought that parasites are able to selectively uptake suramin via receptor-mediated endocytosis of drug that is bound to low-density lipoproteins and to a lesser extent, other serum proteins. Once inside parasites, suramin combines with proteins, especially trypanosomal glycolytic enzymes to inhibit energy metabolism. (https://en.wikipedia.org/wiki/Suramin)

Chemical Structure

Suramin Hexasodium
Suramin Hexasodium
CAS#129-46-4 (sodium)

Theoretical Analysis

MedKoo Cat#: 318784

Name: Suramin Hexasodium

CAS#: 129-46-4 (sodium)

Chemical Formula: C51H34N6Na6O23S6

Exact Mass: 1296.0469

Molecular Weight: 1429.15

Elemental Analysis: C, 42.86; H, 2.40; N, 5.88; Na, 9.65; O, 25.75; S, 13.46

Price and Availability

Size Price Availability Quantity
25mg USD 450.00 2 Weeks
50mg USD 750.00 2 Weeks
100mg USD 1,250.00 2 Weeks
200mg USD 2,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
145-63-1 (free acid) 129-46-4 (sodium)
Synonym
NSC-34936l; NSC34936 ; NSC 34936; BAY 205; Germanin; NF 060; Suramin; Farma; Fourneau;
IUPAC/Chemical Name
sodium 8,8'-((3,3'-((3,3'-(carbonylbis(azanediyl))bis(benzoyl))bis(azanediyl))bis(4-methylbenzoyl))bis(azanediyl))bis(naphthalene-1,3,5-trisulfonate)
InChi Key
VAPNKLKDKUDFHK-UHFFFAOYSA-H
InChi Code
InChI=1S/C51H40N6O23S6.6Na/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80;;;;;;/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80);;;;;;/q;6*+1/p-6
SMILES Code
O=C(NC1=CC(C(NC2=CC(C(NC(C(C3=CC(S([O-])(=O)=O)=C4)=C4S([O-])(=O)=O)=CC=C3S([O-])(=O)=O)=O)=CC=C2C)=O)=CC=C1)NC5=CC(C(NC6=CC(C(NC7=CC=C(S(=O)([O-])=O)C8=CC(S(=O)([O-])=O)=CC(S(=O)([O-])=O)=C78)=O)=CC=C6C)=O)=CC=C5.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in water
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Suramin is used to treat African sleeping sickness and river blindness. It is the treatment of choice for sleeping sickness without central nervous system involvement. It is also used as a research reagent to inhibit the activation of heterotrimeric G proteins in a variety of GPCRs with varying potency. It prevents the association of heteromeric G proteins and therefore the receptors guanine exchange functionality (GEF). With this blockade the GDP will not release from the Gα subunit so it can not be replaced by a GTP and become activated.
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#S21G06M23
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,429.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Liu N, Zhuang S. Tissue protective and anti-fibrotic actions of suramin: new uses of an old drug. Curr Clin Pharmacol. 2011 May;6(2):137-42. Review. PubMed PMID: 21470104. 2: McGeary RP, Bennett AJ, Tran QB, Cosgrove KL, Ross BP. Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem. 2008 Nov;8(13):1384-94. Review. PubMed PMID: 18991754. 3: Doggrell SA. Suramin: potential in acute liver failure. Expert Opin Investig Drugs. 2004 Oct;13(10):1361-3. Review. PubMed PMID: 15461564. 4: Nok AJ. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitol Res. 2003 May;90(1):71-9. Epub 2003 Jan 31. Review. PubMed PMID: 12743807. 5: Lambrecht G, Braun K, Damer M, Ganso M, Hildebrandt C, Ullmann H, Kassack MU, Nickel P. Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists. Curr Pharm Des. 2002;8(26):2371-99. Review. PubMed PMID: 12369951. 6: Siu LL, Moore MJ. Other chemotherapy regimens including mitoxantrone and suramin. Semin Urol Oncol. 1997 Feb;15(1):20-7. Review. PubMed PMID: 9050136. 7: Walther MM, Figg WD, Linehan WM. Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World J Urol. 1996;14 Suppl 1:S8-11. Review. PubMed PMID: 8738403. 8: Lowitt MH, Eisenberger M, Sina B, Kao GF. Cutaneous eruptions from suramin. A clinical and histopathologic study of 60 patients. Arch Dermatol. 1995 Oct;131(10):1147-53. Review. PubMed PMID: 7574831. 9: Eisenberger MA, Sinibaldi V, Reyno L. Suramin. Cancer Pract. 1995 May-Jun;3(3):187-9. Review. PubMed PMID: 7599677. 10: Eisenberger MA, Reyno LM. Suramin. Cancer Treat Rev. 1994 Jul;20(3):259-73. Review. PubMed PMID: 8020006. 11: Rebollo J. [Suramin: pharmacology and antitumor effectiveness of an old parasiticide]. Med Clin (Barc). 1994 Mar 5;102(8):301-5. Review. Spanish. PubMed PMID: 8170229. 12: Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH. Recent research on the biological activity of suramin. Pharmacol Rev. 1993 Jun;45(2):177-203. Review. PubMed PMID: 8396782. 13: Stein CA. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res. 1993 May 15;53(10 Suppl):2239-48. Review. PubMed PMID: 8485709. 14: Larsen AK. Suramin: an anticancer drug with unique biological effects. Cancer Chemother Pharmacol. 1993;32(2):96-8. Review. PubMed PMID: 8387401. 15: Scher HI, Heston WD. Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors. Cancer Treat Res. 1992;59:131-51. Review. PubMed PMID: 1347690. 16: Dorfinger K, Niederle B, Vierhapper H, Astrid W, Czernin S, Nowotny P, Waldhäusl W, Grubeck-Loebenstein B. Suramin and the human adrenocortex: results of experimental and clinical studies. Surgery. 1991 Dec;110(6):1100-5. Review. PubMed PMID: 1660627. 17: LaRocca RV, Cooper MR, Uhrich M, Danesi R, Walther MM, Linehan WM, Myers CE. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin North Am. 1991 Feb;18(1):123-9. Review. PubMed PMID: 1992566. 18: La Rocca RV, Stein CA, Danesi R, Myers CE. Suramin, a novel antitumor compound. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):893-8. Review. PubMed PMID: 2285603. 19: Klijn JG, Setyono-Han B, Bakker GH, van der Burg ME, Bontenbal M, Peters HA, Sieuwerts AM, Berns PM, Foekens JA. Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1089-95. Review. PubMed PMID: 1981013. 20: La Rocca RV, Stein CA, Myers CE. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells. 1990 Apr;2(4):106-15. Review. PubMed PMID: 2202382.